Guardant Health jumps 25% in a week as Medicare test looms
Guardant Health is coming off a volatile week heading into a holiday break, finishing Friday at $118.95 after a fresh FDA approval helped push the shares up about 25% for the week. The Nasdaq cancer test maker surged 17.1% on May 20 as its Guardant360 Liquid CDx blood test cleared a key regulatory hurdle. Shares reached as much as $121.01 during the week, according to price data. Markets are closed at the moment. May 24 falls on a Sunday in New York, and according to Nasdaq’s 2026 holiday calendar, U.S. equity markets will stay shut for Memorial Day on Monday, May 25. Regular trading picks up again Tuesday, giving investors their first shot to react.